Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study.

Details

Serval ID
serval:BIB_2680D836B84F
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study.
Journal
Journal of the European Academy of Dermatology and Venereology
Author(s)
Brüggen M.C., Valencak J., Stranzenbach R., Li N., Stadler R., Jonak C., Bauer W., Porkert S., Blaschke A., Meiss F., Nicolay J.P., Wehkamp U., Schlaak M., Nguyen V.A., Romani N., Cozzio A., Gayathri N., Dimitriou F., French L.E., Dummer R., Guenova E.
ISSN
1468-3083 (Electronic)
ISSN-L
0926-9959
Publication state
Published
Issued date
07/2020
Peer-reviewed
Oui
Volume
34
Number
7
Pages
1489-1495
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive type of haematologic precursor malignancy primarily often manifesting in the skin. We sought to provide a thorough clinical characterization and report our experience on therapeutic approaches to BPDCN.
In the present multicentric retrospective study, we collected all BPDCN cases occurring between 05/1999 and 03/2018 in 10 secondary care centres of the German-Swiss-Austrian cutaneous lymphoma working group.
A total of 37 BPDCN cases were identified and included. Almost 90% of the patients had systemic manifestations (bone marrow, lymph nodes, peripheral blood) in addition to skin involvement. The latter presented with various types of cutaneous lesions: nodular (in more than 2/3) and bruise-like (in 1/3) skin lesions, but also maculopapular exanthema (in circa 1/6). Therapeutically, 22 patients received diverse combinations of chemotherapeutic regimens and/or radiotherapy. Despite initial responses, all of them ultimately relapsed and died from progressive disease. Eleven patients underwent haematopoietic stem cell transplantation (HSCT; autologous HSCT n = 3, allo-HSCT n = 8). The mortality rate among HSCT patients was only 33.33% with a median survival time of 60.5 months.
Our study demonstrates the clinical diversity of cutaneous BPDCN manifestations and the positive development observed after the introduction of HSCT.
Pubmed
Web of science
Create date
23/01/2020 15:33
Last modification date
02/09/2020 5:22
Usage data